Details of the Drug Combination

General Information of Drug Combination (ID: DCFH08P)

Drug Combination Name
Docetaxel Cyclophosphamide
Indication
Disease Entry Status REF
Invasive ductal carcinoma Investigative [1]
Component Drugs Docetaxel   DMDI269 Cyclophosphamide   DM4O2Z7
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: T-47D
Zero Interaction Potency (ZIP) Score: 4.06
Bliss Independence Score: 6.1
Loewe Additivity Score: 5.1
LHighest Single Agent (HSA) Score: 2.79

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Docetaxel
Disease Entry ICD 11 Status REF
Advanced cancer 2A00-2F9Z Approved [2]
Breast carcinoma N.A. Approved [2]
Head and neck cancer 2D42 Approved [2]
Leiomyosarcoma 2B58 Approved [2]
Lung cancer 2C25.0 Approved [2]
Non-small-cell lung cancer 2C25.Y Approved [2]
Prostate adenocarcinoma N.A. Approved [2]
Prostate cancer 2C82.0 Approved [2]
Solid tumour/cancer 2A00-2F9Z Approved [3]
Urinary system neoplasm N.A. Approved [2]
Gastric cancer 2B72 Investigative [2]
Docetaxel Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Tubulin (TUB) TTML2WA NOUNIPROTAC Inhibitor [9]
------------------------------------------------------------------------------------
Docetaxel Interacts with 8 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [10]
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [11]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [12]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [13]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [14]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [15]
TAP-like protein (ABCB9) DT68UV2 ABCB9_HUMAN Substrate [16]
Multidrug resistance-associated protein 7 (ABCC10) DTPS120 MRP7_HUMAN Substrate [17]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 DTP(s)
Docetaxel Interacts with 3 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [18]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [19]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Metabolism [19]
------------------------------------------------------------------------------------
Docetaxel Interacts with 83 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Increases Response To Substance [20]
ATP-binding cassette sub-family C member 2 (ABCC2) OTJSIGV5 MRP2_HUMAN Increases ADR [21]
Multidrug resistance-associated protein 1 (ABCC1) OTGUN89S MRP1_HUMAN Increases Expression [22]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases Response To Substance [20]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [23]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [24]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Decreases Expression [25]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Increases Expression [25]
Progesterone receptor (PGR) OT0FZ3QE PRGR_HUMAN Decreases Expression [25]
Aromatase (CYP19A1) OTZ6XF74 CP19A_HUMAN Decreases Expression [25]
Prostaglandin G/H synthase 2 (PTGS2) OT75U9M4 PGH2_HUMAN Increases Expression [25]
Dihydropyrimidine dehydrogenase (DPYD) OTWRF2NR DPYD_HUMAN Decreases Activity [6]
Tumor necrosis factor receptor superfamily member 10A (TNFRSF10A) OTBPCU2O TR10A_HUMAN Increases Expression [26]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) OTA1CPBV TR10B_HUMAN Increases Expression [26]
Bcl-2-like protein 11 (BCL2L11) OTNQQWFJ B2L11_HUMAN Increases Degradation [27]
Nuclear receptor subfamily 1 group I member 2 (NR1I2) OTC5U0N5 NR1I2_HUMAN Increases Activity [28]
PC4 and SFRS1-interacting protein (PSIP1) OT4YAFUS PSIP1_HUMAN Increases Cleavage [29]
RAF proto-oncogene serine/threonine-protein kinase (RAF1) OT51LSFO RAF1_HUMAN Increases Expression [30]
Granulocyte-macrophage colony-stimulating factor (CSF2) OT1M7D28 CSF2_HUMAN Increases Secretion [31]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Expression [7]
Transcription factor Jun (JUN) OTCYBO6X JUN_HUMAN Increases Phosphorylation [32]
Protein kinase C beta type (PRKCB) OTYQ0656 KPCB_HUMAN Increases Phosphorylation [33]
Keratin, type I cytoskeletal 18 (KRT18) OTVLQFIP K1C18_HUMAN Increases Expression [34]
Cyclin-dependent kinase 1 (CDK1) OTW1SC2N CDK1_HUMAN Increases Activity [35]
Prostate-specific antigen (KLK3) OTFGSBFJ KLK3_HUMAN Decreases Expression [36]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [32]
Androgen receptor (AR) OTUBKAZZ ANDR_HUMAN Decreases Expression [37]
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Increases Expression [38]
Natriuretic peptides B (NPPB) OTSN2IPY ANFB_HUMAN Increases Expression [39]
Cyclic AMP-dependent transcription factor ATF-3 (ATF3) OTC1UOHP ATF3_HUMAN Decreases Expression [40]
Growth arrest and DNA damage-inducible protein GADD45 alpha (GADD45A) OTDRV63V GA45A_HUMAN Decreases Expression [40]
Cyclin-dependent kinase 2 (CDK2) OTB5DYYZ CDK2_HUMAN Increases Activity [35]
Tumor necrosis factor receptor superfamily member 6 (FAS) OTP9XG86 TNR6_HUMAN Increases Expression [41]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Increases Phosphorylation [30]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Increases Phosphorylation [30]
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Decreases Phosphorylation [8]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Decreases Expression [40]
Signal transducer and activator of transcription 3 (STAT3) OTAAGKYZ STAT3_HUMAN Decreases Phosphorylation [42]
Caspase-2 (CASP2) OTUDYSPP CASP2_HUMAN Increases Activity [29]
Cyclin-dependent kinase inhibitor 2A (CDKN2A) OTN0ZWAE CDN2A_HUMAN Decreases Expression [43]
Proliferation marker protein Ki-67 (MKI67) OTA8N1QI KI67_HUMAN Decreases Expression [23]
Caspase-7 (CASP7) OTAPJ040 CASP7_HUMAN Increases Activity [44]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Activity [45]
E3 ubiquitin-protein ligase Mdm2 (MDM2) OTOVXARF MDM2_HUMAN Increases Expression [7]
Focal adhesion kinase 1 (PTK2) OT3Q1JDY FAK1_HUMAN Increases Cleavage [46]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Expression [47]
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) OT2YYI1A MCL1_HUMAN Increases Expression [27]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Increases Activity [46]
Bcl-2 homologous antagonist/killer (BAK1) OTDP6ILW BAK_HUMAN Increases Activity [27]
Bcl2-associated agonist of cell death (BAD) OT63ERYM BAD_HUMAN Decreases Phosphorylation [27]
ELL-associated factor 2 (EAF2) OTSOET5L EAF2_HUMAN Decreases Expression [40]
Small integral membrane protein 14 (SMIM14) OT47IF19 SIM14_HUMAN Decreases Expression [40]
Protein FAM117A (FAM117A) OT2FBGGV F117A_HUMAN Decreases Expression [40]
Delta-like protein 4 (DLL4) OTRA4K2V DLL4_HUMAN Increases Expression [44]
Tumor necrosis factor receptor superfamily member 19 (TNFRSF19) OTTVT4MB TNR19_HUMAN Decreases Expression [40]
Tropomodulin-2 (TMOD2) OTTTUH2W TMOD2_HUMAN Decreases Expression [40]
Flavin-containing monooxygenase 3 (FMO3) OT1G2EV3 FMO3_HUMAN Affects Response To Substance [48]
Kinesin heavy chain isoform 5A (KIF5A) OT3ETTI6 KIF5A_HUMAN Decreases Response To Substance [49]
Proteinase-activated receptor 1 (F2R) OT4WVWBO PAR1_HUMAN Decreases Response To Substance [50]
ATP-binding cassette sub-family G member 1 (ABCG1) OT5BG6MK ABCG1_HUMAN Affects Response To Substance [48]
Regulator of G-protein signaling 17 (RGS17) OT5RVUDS RGS17_HUMAN Increases Response To Substance [51]
Mitotic checkpoint serine/threonine-protein kinase BUB1 beta (BUB1B) OT8KME51 BUB1B_HUMAN Affects Response To Substance [52]
Epidermal growth factor receptor (EGFR) OTAPLO1S EGFR_HUMAN Decreases Response To Substance [53]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Decreases Response To Substance [54]
Superoxide dismutase , mitochondrial (SOD2) OTIWXGZ9 SODM_HUMAN Decreases Response To Substance [55]
Cytochrome P450 1A2 (CYP1A2) OTLLBX48 CP1A2_HUMAN Affects Response To Substance [48]
Glutathione S-transferase P (GSTP1) OTLP0A0Y GSTP1_HUMAN Increases Response To Substance [20]
Receptor tyrosine-protein kinase erbB-2 (ERBB2) OTOAUNCK ERBB2_HUMAN Increases Response To Substance [56]
Kinesin-like protein KIFC3 (KIFC3) OTOPD4QO KIFC3_HUMAN Decreases Response To Substance [49]
Regulator of G-protein signaling 10 (RGS10) OTQ8N1QH RGS10_HUMAN Increases Response To Substance [51]
E3 ubiquitin-protein ligase CHFR (CHFR) OTRAD2TT CHFR_HUMAN Decreases Response To Substance [57]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Decreases Response To Substance [58]
Cell surface glycoprotein MUC18 (MCAM) OTT8XKGE MUC18_HUMAN Decreases Response To Substance [59]
Kinesin-like protein KIF12 (KIF12) OTTALNDD KIF12_HUMAN Decreases Response To Substance [49]
Nucleophosmin (NPM1) OTTBYYT0 NPM_HUMAN Decreases Response To Substance [60]
Flavin-containing monooxygenase 2 (FMO2) OTUJUL9S FMO2_HUMAN Affects Response To Substance [48]
NADPH--cytochrome P450 reductase (POR) OTVIDOCH NCPR_HUMAN Increases Response To Substance [20]
Kinesin-like protein KIF14 (KIF14) OTXHT4JM KIF14_HUMAN Decreases Response To Substance [61]
Mitotic spindle assembly checkpoint protein MAD2A (MAD2L1) OTXNGZCG MD2L1_HUMAN Affects Response To Substance [52]
Cellular retinoic acid-binding protein 2 (CRABP2) OTY01V9G RABP2_HUMAN Affects Response To Substance [62]
Cytochrome P450 1B1 (CYP1B1) OTYXFLSD CP1B1_HUMAN Affects Response To Substance [63]
Cytochrome P450 2D6 (CYP2D6) OTZJC802 CP2D6_HUMAN Affects Response To Substance [48]
ATP-binding cassette sub-family C member 6 (ABCC6) OTZT0LKT MRP6_HUMAN Affects Response To Substance [48]
------------------------------------------------------------------------------------
⏷ Show the Full List of 83 DOT(s)
Indication(s) of Cyclophosphamide
Disease Entry ICD 11 Status REF
Advanced cancer 2A00-2F9Z Approved [4]
Central nervous system neoplasm N.A. Approved [4]
Glioblastoma 2A00 Approved [4]
Immunodeficiency 4A00-4A85 Approved [4]
Inflammatory breast cancer 2C62 Approved [4]
Lupus nephritis 4A40.0Y Approved [4]
Lymphoma 2A80-2A86 Approved [4]
Multiple sclerosis 8A40 Approved [4]
Mycosis fungoides 2B01 Approved [4]
Plasma cell myeloma 2A83.1 Approved [4]
Solid tumour/cancer 2A00-2F9Z Approved [5]
Classic Hodgkin lymphoma N.A. Investigative [4]
Neuroblastoma 2D11.2 Investigative [4]
Retinoblastoma 2D02.2 Investigative [4]
Scleroderma 4A42 Investigative [4]
Cyclophosphamide Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Human Deoxyribonucleic acid (hDNA) TTUTN1I NOUNIPROTAC Modulator [70]
------------------------------------------------------------------------------------
Cyclophosphamide Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 4 (ABCC4) DTCSGPB MRP4_HUMAN Substrate [71]
------------------------------------------------------------------------------------
Cyclophosphamide Interacts with 8 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [72]
Cytochrome P450 2A6 (CYP2A6) DEJVYAZ CP2A6_HUMAN Metabolism [73]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Metabolism [74]
Cytochrome P450 2C18 (CYP2C18) DEZMWRE CP2CI_HUMAN Metabolism [73]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [75]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [76]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Metabolism [77]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Metabolism [78]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 DME(s)
Cyclophosphamide Interacts with 225 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 2C8 (CYP2C8) OTHCWT42 CP2C8_HUMAN Increases Activity [79]
Cytochrome P450 2C18 (CYP2C18) OTY687L9 CP2CI_HUMAN Increases Activity [79]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Increases Expression [80]
Cytochrome P450 2B6 (CYP2B6) OTOYO4S7 CP2B6_HUMAN Increases Hydroxylation [81]
Glucose-6-phosphate 1-dehydrogenase (G6PD) OT300SMK G6PD_HUMAN Increases ADR [64]
Cytochrome P450 2D6 (CYP2D6) OTZJC802 CP2D6_HUMAN Increases Metabolism [82]
Cholinesterase (BCHE) OTOH3WQ9 CHLE_HUMAN Decreases Activity [83]
Actin, cytoplasmic 1 (ACTB) OT1MCP2F ACTB_HUMAN Decreases Expression [84]
Cytochrome P450 1B1 (CYP1B1) OTYXFLSD CP1B1_HUMAN Decreases Expression [84]
Band 4.1-like protein 2 (EPB41L2) OT6UABPM E41L2_HUMAN Decreases Expression [85]
Receptor activity-modifying protein 1 (RAMP1) OT7UT2XB RAMP1_HUMAN Increases Expression [85]
Cystatin-F (CST7) OTQWZUVQ CYTF_HUMAN Decreases Expression [85]
Kelch repeat and BTB domain-containing protein 11 (KBTBD11) OTBOY3WH KBTBB_HUMAN Decreases Expression [85]
Aldehyde dehydrogenase 1A1 (ALDH1A1) OTCUWZKB AL1A1_HUMAN Increases Expression [85]
Carbonic anhydrase 2 (CA2) OTJRMUAG CAH2_HUMAN Decreases Expression [85]
Aldehyde dehydrogenase, mitochondrial (ALDH2) OTKJ9I3N ALDH2_HUMAN Increases Expression [85]
Tyrosine-protein kinase Fyn (FYN) OTLSLVZS FYN_HUMAN Increases Expression [85]
Procathepsin L (CTSL) OTYTUW29 CATL1_HUMAN Increases Expression [85]
Galectin-1 (LGALS1) OT8LDFWR LEG1_HUMAN Increases Expression [85]
SPARC (SPARC) OTPN90H0 SPRC_HUMAN Increases Expression [85]
Pro-cathepsin H (CTSH) OTLFL0DG CATH_HUMAN Increases Expression [85]
Non-secretory ribonuclease (RNASE2) OT8Z4FNE RNAS2_HUMAN Decreases Expression [85]
Transcriptional regulator ERG (ERG) OTOTX9VU ERG_HUMAN Increases Expression [85]
Tissue factor (F3) OT3MSU3B TF_HUMAN Decreases Expression [85]
Cytochrome c oxidase subunit 7A2, mitochondrial (COX7A2) OTVT146E CX7A2_HUMAN Decreases Expression [85]
Methylated-DNA--protein-cysteine methyltransferase (MGMT) OT40A9WH MGMT_HUMAN Decreases Expression [85]
Bactericidal permeability-increasing protein (BPI) OTNN9LJ5 BPI_HUMAN Decreases Expression [85]
Arachidonate 5-lipoxygenase-activating protein (ALOX5AP) OT0DH40W AL5AP_HUMAN Decreases Expression [85]
Interferon-induced GTP-binding protein Mx2 (MX2) OT05NF37 MX2_HUMAN Decreases Expression [85]
Amine oxidase A (MAOA) OT8NIWMQ AOFA_HUMAN Increases Expression [85]
Myeloblastin (PRTN3) OT72MHP7 PRTN3_HUMAN Decreases Expression [85]
Protein S100-P (S100P) OTJCXNJG S100P_HUMAN Decreases Expression [85]
Caspase-1 (CASP1) OTZ3YQFU CASP1_HUMAN Decreases Expression [85]
Myristoylated alanine-rich C-kinase substrate (MARCKS) OT7N056G MARCS_HUMAN Increases Expression [85]
Transmembrane 4 L6 family member 1 (TM4SF1) OTY0ECQN T4S1_HUMAN Increases Expression [85]
Intercellular adhesion molecule 3 (ICAM3) OTTZ5A5D ICAM3_HUMAN Decreases Expression [85]
P2Y purinoceptor 2 (P2RY2) OT47XN46 P2RY2_HUMAN Decreases Expression [85]
Glycine receptor subunit beta (GLRB) OTF37UG4 GLRB_HUMAN Increases Expression [85]
C-C chemokine receptor type 8 (CCR8) OTSCMH06 CCR8_HUMAN Decreases Expression [85]
Ras-related protein R-Ras2 (RRAS2) OT83NCEB RRAS2_HUMAN Increases Expression [85]
Bcl-2-interacting killer (BIK) OTTH1T3D BIK_HUMAN Decreases Expression [85]
Angiopoietin-1 (ANGPT1) OTVZ1NG3 ANGP1_HUMAN Increases Expression [85]
Fascin (FSCN1) OTTGIHTM FSCN1_HUMAN Increases Expression [85]
Pleckstrin homology-like domain family A member 2 (PHLDA2) OTMV9DPP PHLA2_HUMAN Increases Expression [85]
Testis-expressed protein 30 (TEX30) OT87WEPQ TEX30_HUMAN Decreases Expression [85]
Ras-related GTP-binding protein A (RRAGA) OTKISLG4 RRAGA_HUMAN Decreases Expression [85]
Cilium assembly protein DZIP1 (DZIP1) OTBVPO66 DZIP1_HUMAN Increases Expression [85]
RNA-binding protein with multiple splicing (RBPMS) OT1RDKR9 RBPMS_HUMAN Increases Expression [85]
Membrane-spanning 4-domains subfamily A member 3 (MS4A3) OT0CEJOO MS4A3_HUMAN Decreases Expression [85]
Rho GTPase-activating protein 7 (DLC1) OTP8LMCR RHG07_HUMAN Increases Expression [85]
MyoD family inhibitor domain-containing protein (MDFIC) OTSRYBWZ MDFIC_HUMAN Decreases Expression [85]
Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-12 (GNG12) OTOGF42G GBG12_HUMAN Increases Expression [85]
Cyclic AMP-dependent transcription factor ATF-5 (ATF5) OT03QCLM ATF5_HUMAN Decreases Expression [85]
PALM2-AKAP2 fusion protein (PALM2AKAP2) OTI618VF PLAK2_HUMAN Increases Expression [85]
Dihydropyrimidinase-related protein 4 (DPYSL4) OT3SBS2S DPYL4_HUMAN Increases Expression [65]
Integral membrane protein GPR137B (GPR137B) OT1CINQQ G137B_HUMAN Increases Expression [65]
Glutaminase kidney isoform, mitochondrial (GLS) OTGOZG2M GLSK_HUMAN Increases Expression [65]
Urokinase-type plasminogen activator (PLAU) OTX0QGKK UROK_HUMAN Increases Expression [65]
Ubiquitin-like protein ISG15 (ISG15) OT53QQ7N ISG15_HUMAN Increases Expression [65]
Early growth response protein 1 (EGR1) OTCP6XGZ EGR1_HUMAN Increases Expression [65]
Stomatin (STOM) OTC8R6EH STOM_HUMAN Increases Expression [65]
Cellular retinoic acid-binding protein 2 (CRABP2) OTY01V9G RABP2_HUMAN Increases Expression [65]
Tyrosine-protein kinase receptor UFO (AXL) OTKA2SUX UFO_HUMAN Increases Expression [65]
14-3-3 protein sigma (SFN) OTLJCZ1U 1433S_HUMAN Increases Expression [65]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Increases Expression [65]
Tumor necrosis factor ligand superfamily member 9 (TNFSF9) OTV9L89D TNFL9_HUMAN Increases Expression [65]
Galectin-7 (LGALS7) OTMSVI7R LEG7_HUMAN Increases Expression [65]
Rho GDP-dissociation inhibitor 2 (ARHGDIB) OT9PD6CS GDIR2_HUMAN Increases Expression [65]
Epithelial membrane protein 1 (EMP1) OTSZHUHQ EMP1_HUMAN Increases Expression [65]
Epithelial membrane protein 3 (EMP3) OTODMJ1D EMP3_HUMAN Increases Expression [65]
Protein ripply3 (RIPPLY3) OT1HK35I DSCR6_HUMAN Increases Expression [65]
Pro-neuregulin-1, membrane-bound isoform (NRG1) OTZO6F1X NRG1_HUMAN Increases Expression [65]
Antigen peptide transporter 1 (TAP1) OTJL27PW TAP1_HUMAN Increases Expression [65]
Laminin subunit gamma-2 (LAMC2) OTJMTM72 LAMC2_HUMAN Increases Expression [65]
Filamin-C (FLNC) OT3F8J6Y FLNC_HUMAN Increases Expression [65]
Immediate early response gene 5 protein (IER5) OTJPTXMD IER5_HUMAN Increases Expression [65]
Keratin, type II cytoskeletal 80 (KRT80) OTAU54U3 K2C80_HUMAN Increases Expression [65]
Neuropilin and tolloid-like protein 2 (NETO2) OT0YAMC0 NETO2_HUMAN Increases Expression [65]
UDP-GalNAc:beta-1,3-N-acetylgalactosaminyltransferase 2 (B3GALNT2) OTOF6O2B B3GL2_HUMAN Increases Expression [65]
Phospholipase ABHD3 (ABHD3) OTH8P977 ABHD3_HUMAN Increases Expression [65]
Tumor necrosis factor receptor superfamily member 14 (TNFRSF14) OTB82PFO TNR14_HUMAN Increases Expression [65]
Major histocompatibility complex class I-related gene protein (MR1) OTZU3XX7 HMR1_HUMAN Increases Expression [65]
Tumor necrosis factor receptor superfamily member 27 (EDA2R) OTJLAIIH TNR27_HUMAN Increases Expression [65]
Stathmin-3 (STMN3) OT20F289 STMN3_HUMAN Increases Expression [65]
Solute carrier family 2, facilitated glucose transporter member 6 (SLC2A6) OTVUZCLG GTR6_HUMAN Increases Expression [65]
Endothelial protein C receptor (PROCR) OTRHED17 EPCR_HUMAN Increases Expression [65]
Serine/threonine-protein kinase Sgk1 (SGK1) OT301T1U SGK1_HUMAN Decreases Expression [66]
Interferon-related developmental regulator 1 (IFRD1) OT4SQMLQ IFRD1_HUMAN Decreases Expression [66]
Kinesin-like protein KIF21B (KIF21B) OTFXFIU3 KI21B_HUMAN Decreases Expression [66]
Large neutral amino acids transporter small subunit 3 (SLC43A1) OTQJQY3S LAT3_HUMAN Decreases Expression [66]
Cystatin-A (CSTA) OT1K68KE CYTA_HUMAN Decreases Expression [66]
Amino acid transporter heavy chain SLC3A2 (SLC3A2) OTBR33M9 4F2_HUMAN Decreases Expression [66]
Asparagine synthetase (ASNS) OT8R922G ASNS_HUMAN Decreases Expression [66]
Endoplasmic reticulum chaperone BiP (HSPA5) OTFUIRAO BIP_HUMAN Increases Expression [66]
Bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase, mitochondrial (MTHFD2) OT1LQSGX MTDC_HUMAN Decreases Expression [66]
CCAAT/enhancer-binding protein beta (CEBPB) OTM9MQIA CEBPB_HUMAN Decreases Expression [66]
Protein EVI2A (EVI2A) OTR8RUXQ EVI2A_HUMAN Decreases Expression [66]
Tumor necrosis factor receptor superfamily member 6 (FAS) OTP9XG86 TNR6_HUMAN Decreases Expression [66]
DnaJ homolog subfamily B member 1 (DNAJB1) OTCOSEVH DNJB1_HUMAN Increases Expression [66]
DNA damage-inducible transcript 3 protein (DDIT3) OTI8YKKE DDIT3_HUMAN Decreases Expression [66]
B-cell lymphoma 6 protein (BCL6) OTQAWWO1 BCL6_HUMAN Decreases Expression [66]
Radiation-inducible immediate-early gene IEX-1 (IER3) OTZJI5FZ IEX1_HUMAN Decreases Expression [66]
Cysteine--tRNA ligase, cytoplasmic (CARS1) OTOUZF6O SYCC_HUMAN Decreases Expression [66]
Sestrin-2 (SESN2) OT889IXY SESN2_HUMAN Decreases Expression [66]
Hydroxymethylglutaryl-CoA synthase, cytoplasmic (HMGCS1) OTCO26FV HMCS1_HUMAN Increases Expression [66]
DNA-binding protein inhibitor ID-2 (ID2) OT0U1D53 ID2_HUMAN Decreases Expression [66]
Early activation antigen CD69 (CD69) OTGJHSVP CD69_HUMAN Decreases Expression [66]
Transmembrane protein 267 (TMEM267) OTEAAVK7 TM267_HUMAN Decreases Expression [66]
Baculoviral IAP repeat-containing protein 3 (BIRC3) OT3E95KB BIRC3_HUMAN Decreases Expression [66]
Isopentenyl-diphosphate Delta-isomerase 1 (IDI1) OTGM06VJ IDI1_HUMAN Increases Expression [66]
N-arachidonyl glycine receptor (GPR18) OTL2VFIV GPR18_HUMAN Decreases Expression [66]
Nuclear receptor coactivator 7 (NCOA7) OT2CNBOG NCOA7_HUMAN Decreases Expression [66]
Alanine aminotransferase 2 (GPT2) OTS5VF7N ALAT2_HUMAN Decreases Expression [66]
Nanos homolog 1 (NANOS1) OT3UNZZY NANO1_HUMAN Increases Expression [66]
Heat shock protein 105 kDa (HSPH1) OTVRR73T HS105_HUMAN Increases Expression [66]
Insulin gene enhancer protein ISL-2 (ISL2) OT43PD2V ISL2_HUMAN Decreases Expression [66]
E3 ubiquitin-protein ligase pellino homolog 1 (PELI1) OTMLBCLC PELI1_HUMAN Decreases Expression [66]
Centriolar and ciliogenesis-associated protein HYLS1 (HYLS1) OT3SW5UC HYLS1_HUMAN Decreases Expression [66]
Tribbles homolog 3 (TRIB3) OTG5OS7X TRIB3_HUMAN Decreases Expression [66]
Glutathione-specific gamma-glutamylcyclotransferase 1 (CHAC1) OTJGE772 CHAC1_HUMAN Decreases Expression [66]
Transmembrane 6 superfamily member 1 (TM6SF1) OTQR4I2N TM6S1_HUMAN Decreases Expression [66]
Protein FAM107B (FAM107B) OT5RG4J0 F107B_HUMAN Decreases Expression [66]
Lysine-rich coiled-coil protein 1 (KRCC1) OTMMV6WZ KRCC1_HUMAN Decreases Expression [66]
DnaJ homolog subfamily B member 4 (DNAJB4) OTUD01BK DNJB4_HUMAN Increases Expression [66]
SLAM family member 5 (CD84) OTAY5B0F SLAF5_HUMAN Increases Expression [66]
Cystine/glutamate transporter (SLC7A11) OTKJ6PXW XCT_HUMAN Decreases Expression [66]
Nuclear factor erythroid 2-related factor 3 (NFE2L3) OT1MGXT0 NF2L3_HUMAN Decreases Expression [66]
Dual specificity protein phosphatase 10 (DUSP10) OTNG467B DUS10_HUMAN Decreases Expression [66]
Apoptotic protease-activating factor 1 (APAF1) OTJWIVY0 APAF_HUMAN Decreases Expression [67]
Transmembrane protease serine 2 (TMPRSS2) OTN44YQ5 TMPS2_HUMAN Increases Expression [86]
Growth arrest-specific protein 2 (GAS2) OT50JKXQ GAS2_HUMAN Increases Expression [87]
Lysine-specific histone demethylase 1A (KDM1A) OT85JXS5 KDM1A_HUMAN Increases Expression [88]
Slit homolog 1 protein (SLIT1) OT35RBNT SLIT1_HUMAN Decreases Expression [68]
DnaJ homolog subfamily B member 6 (DNAJB6) OTMHIIAN DNJB6_HUMAN Increases Expression [87]
Nuclear receptor subfamily 1 group I member 2 (NR1I2) OTC5U0N5 NR1I2_HUMAN Increases Activity [28]
Follitropin subunit beta (FSHB) OTGLS283 FSHB_HUMAN Increases Expression [89]
Thymidine kinase, cytosolic (TK1) OTY5JFM1 KITH_HUMAN Increases Mutagenesis [90]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Mutagenesis [91]
Endothelin-1 (EDN1) OTZCACEG EDN1_HUMAN Increases Expression [92]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases Expression [28]
Heme oxygenase 1 (HMOX1) OTC1W6UX HMOX1_HUMAN Decreases Expression [93]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [94]
Heat shock 70 kDa protein 1A (HSPA1A) OTKGIE76 HS71A_HUMAN Increases Expression [95]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Increases Expression [96]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Increases Expression [97]
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Increases Phosphorylation [98]
Natriuretic peptides B (NPPB) OTSN2IPY ANFB_HUMAN Increases Expression [92]
Troponin I, cardiac muscle (TNNI3) OT65E12V TNNI3_HUMAN Increases Expression [92]
Tumor necrosis factor alpha-induced protein 3 (TNFAIP3) OTVLI4DD TNAP3_HUMAN Increases Expression [99]
Growth arrest and DNA damage-inducible protein GADD45 alpha (GADD45A) OTDRV63V GA45A_HUMAN Increases Expression [67]
Endothelin receptor type B (EDNRB) OTLLZV3P EDNRB_HUMAN Increases Expression [68]
Insulin-like growth factor-binding protein 5 (IGFBP5) OTRE5V0C IBP5_HUMAN Decreases Expression [68]
DNA cytosine-5)-methyltransferase 1 (DNMT1) OTM2DGTK DNMT1_HUMAN Decreases Methylation [88]
Proteasome subunit alpha type-5 (PSMA5) OT38E6Y1 PSA5_HUMAN Increases Expression [87]
HLA class I histocompatibility antigen, alpha chain F (HLA-F) OT76CM19 HLAF_HUMAN Increases Expression [68]
Phospholipid hydroperoxide glutathione peroxidase GPX4 (GPX4) OTRAFFX2 GPX4_HUMAN Increases Expression [87]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Expression [97]
Cytosolic purine 5'-nucleotidase (NT5C2) OTJMF66Z 5NTC_HUMAN Increases Expression [68]
Tumor protein D52 (TPD52) OTPKSK43 TPD52_HUMAN Decreases Expression [99]
Potassium voltage-gated channel subfamily KQT member 4 (KCNQ4) OT29B58J KCNQ4_HUMAN Decreases Expression [68]
Heterogeneous nuclear ribonucleoprotein K (HNRNPK) OTNPRM8U HNRPK_HUMAN Increases Expression [87]
Protein BTG2 (BTG2) OTZF6K1H BTG2_HUMAN Increases Expression [67]
Runt-related transcription factor 3 (RUNX3) OTITK1XD RUNX3_HUMAN Decreases Expression [68]
Calicin (CCIN) OTRFZOT0 CALI_HUMAN Increases Expression [87]
Programmed cell death protein 4 (PDCD4) OTZ6NXUX PDCD4_HUMAN Decreases Expression [99]
Ribonucleoside-diphosphate reductase subunit M2 B (RRM2B) OTE8GBUR RIR2B_HUMAN Increases Expression [100]
Partitioning defective 3 homolog (PARD3) OTH5BPLO PARD3_HUMAN Decreases Expression [68]
GATOR1 complex protein NPRL2 (NPRL2) OTOB10MO NPRL2_HUMAN Decreases Expression [68]
F-box/WD repeat-containing protein 7 (FBXW7) OTJXE4OT FBXW7_HUMAN Increases Expression [67]
Rho guanine nucleotide exchange factor 26 (ARHGEF26) OTX0U8PX ARHGQ_HUMAN Increases Expression [68]
G-protein coupled receptor 20 (GPR20) OTPCR8F7 GPR20_HUMAN Increases Expression [68]
Angiotensin-converting enzyme 2 (ACE2) OTTRZGU7 ACE2_HUMAN Decreases Expression [86]
Polyadenylate-binding protein-interacting protein 1 (PAIP1) OTL2F5T5 PAIP1_HUMAN Decreases Expression [68]
Large subunit GTPase 1 homolog (LSG1) OTDAXJ9L LSG1_HUMAN Decreases Expression [68]
Glyoxalase domain-containing protein 4 (GLOD4) OTBJKFXA GLOD4_HUMAN Decreases Expression [68]
DNA-directed DNA/RNA polymerase mu (POLM) OT0SRIP4 DPOLM_HUMAN Increases Expression [68]
Ubiquitin-like-conjugating enzyme ATG3 (ATG3) OT28VBVK ATG3_HUMAN Decreases Expression [68]
Regulator of telomere elongation helicase 1 (RTEL1) OTI3PJCT RTEL1_HUMAN Increases Expression [87]
FK506-binding protein-like (FKBPL) OTR9ND6K FKBPL_HUMAN Increases Expression [97]
Mitochondrial pyruvate carrier 2 (MPC2) OT0GHXGG MPC2_HUMAN Affects Response To Substance [69]
Krueppel-like factor 5 (KLF5) OT1ABI9N KLF5_HUMAN Affects Response To Substance [69]
Galactocerebrosidase (GALC) OT1F6BZK GALC_HUMAN Affects Response To Substance [69]
Granulocyte-macrophage colony-stimulating factor (CSF2) OT1M7D28 CSF2_HUMAN Affects Activity [101]
Superoxide dismutase (SOD1) OT39TA1L SODC_HUMAN Increases ADR [64]
Krueppel-like factor 4 (KLF4) OT4O9RQW KLF4_HUMAN Decreases Response To Substance [102]
D-beta-hydroxybutyrate dehydrogenase, mitochondrial (BDH1) OT62RL5P BDH_HUMAN Affects Response To Substance [69]
Melanoma-associated antigen D1 (MAGED1) OT6EOLFC MAGD1_HUMAN Affects Response To Substance [69]
Prostaglandin G/H synthase 2 (PTGS2) OT75U9M4 PGH2_HUMAN Affects Response To Substance [69]
Pro-adrenomedullin (ADM) OT7T0TA4 ADML_HUMAN Affects Response To Substance [69]
Peptidyl-prolyl cis-trans isomerase FKBP1B (FKBP1B) OT8CMPB2 FKB1B_HUMAN Affects Response To Substance [69]
L-lactate dehydrogenase B chain (LDHB) OT9B1CT3 LDHB_HUMAN Affects Response To Substance [69]
Epsilon-sarcoglycan (SGCE) OT9F17JB SGCE_HUMAN Affects Response To Substance [69]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Increases Response To Substance [103]
Aldehyde dehydrogenase, dimeric NADP-preferring (ALDH3A1) OTAYZZE6 AL3A1_HUMAN Affects Response To Substance [104]
Sterol O-acyltransferase 1 (SOAT1) OTB4Y5RJ SOAT1_HUMAN Affects Response To Substance [69]
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) OTB97VIK IF2B3_HUMAN Affects Response To Substance [69]
Cochlin (COCH) OTBEHD89 COCH_HUMAN Affects Response To Substance [69]
Fibronectin type III domain-containing protein 3B (FNDC3B) OTBILGDR FND3B_HUMAN Affects Response To Substance [69]
Tropomyosin alpha-1 chain (TPM1) OTD73X6R TPM1_HUMAN Affects Response To Substance [69]
Very long chain fatty acid elongase 2 (ELOVL2) OTDAF6U3 ELOV2_HUMAN Affects Response To Substance [69]
Glutathione peroxidase 1 (GPX1) OTE2O72Q GPX1_HUMAN Increases ADR [64]
Protein AF1q (MLLT11) OTG5RVHC AF1Q_HUMAN Decreases Response To Substance [105]
Troponin I, fast skeletal muscle (TNNI2) OTGGZFSC TNNI2_HUMAN Increases ADR [64]
Multidrug resistance-associated protein 1 (ABCC1) OTGUN89S MRP1_HUMAN Decreases Response To Substance [106]
Tomoregulin-1 (TMEFF1) OTH6M3CH TEFF1_HUMAN Affects Response To Substance [69]
DNA damage-inducible transcript 4 protein (DDIT4) OTHY8SY4 DDIT4_HUMAN Affects Response To Substance [69]
Ribosomal protein S6 kinase alpha-2 (RPS6KA2) OTIOYUSU KS6A2_HUMAN Affects Response To Substance [69]
Superoxide dismutase , mitochondrial (SOD2) OTIWXGZ9 SODM_HUMAN Affects Response To Substance [107]
Insulin-like growth factor-binding protein 3 (IGFBP3) OTIX63TX IBP3_HUMAN Affects Response To Substance [69]
Osteopontin (SPP1) OTJGC23Y OSTP_HUMAN Affects Response To Substance [69]
Heat shock cognate 71 kDa protein (HSPA8) OTJI2RCI HSP7C_HUMAN Affects Response To Substance [69]
Nidogen-1 (NID1) OTKLBLS6 NID1_HUMAN Affects Response To Substance [69]
Glutathione reductase, mitochondrial (GSR) OTM2TUYM GSHR_HUMAN Increases ADR [64]
Homeobox protein Hox-A1 (HOXA1) OTMSOJ7D HXA1_HUMAN Affects Response To Substance [69]
Trypsin-3 (PRSS3) OTN3S5YB TRY3_HUMAN Affects Response To Substance [69]
Melanoma-associated antigen D4 (MAGED4B) OTO37U7W MAGD4_HUMAN Affects Response To Substance [69]
Opsin-3 (OPN3) OTON6BFU OPN3_HUMAN Affects Response To Substance [69]
Interleukin-1 alpha (IL1A) OTPSGILV IL1A_HUMAN Affects Response To Substance [108]
Complement factor I (CFI) OTQYYX0P CFAI_HUMAN Affects Response To Substance [69]
Heat shock-related 70 kDa protein 2 (HSPA2) OTSDET7B HSP72_HUMAN Affects Response To Substance [69]
Cytochrome P450 3A5 (CYP3A5) OTSXFBXB CP3A5_HUMAN Affects Response To Substance [109]
Max-interacting protein 1 (MXI1) OTUQ9E0D MXI1_HUMAN Affects Response To Substance [69]
Glycogen debranching enzyme (AGL) OTWBM7WY GDE_HUMAN Affects Response To Substance [69]
Myosin-10 (MYH10) OTXN2WXS MYH10_HUMAN Affects Response To Substance [69]
Sal-like protein 1 (SALL1) OTYYZGLH SALL1_HUMAN Affects Response To Substance [69]
------------------------------------------------------------------------------------
⏷ Show the Full List of 225 DOT(s)

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adenocarcinoma DC0S7OE DU-145 Investigative [110]
Clear cell renal cell carcinoma DC57EOD TK-10 Investigative [110]
High grade ovarian serous adenocarcinoma DC1WKXV OVCAR-8 Investigative [110]
Breast adenocarcinoma DC612QV MDA-MB-468 Investigative [1]
------------------------------------------------------------------------------------

References

1 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
2 Docetaxel FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6809).
4 Cyclophosphamide FDA Label
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7154).
6 Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines. Int J Cancer. 2006 Aug 15;119(4):783-91.
7 Induction of tubulin by docetaxel is associated with p53 status in human non small cell lung cancer cell lines. Int J Cancer. 2006 Jan 15;118(2):317-25. doi: 10.1002/ijc.21372.
8 Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells. Int J Cancer. 2005 Jun 20;115(3):484-92. doi: 10.1002/ijc.20878.
9 Docetaxel: a review of its use in metastatic breast cancer. Drugs. 2005;65(17):2513-31.
10 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
11 Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone. Drug Metab Dispos. 2009 Jan;37(1):129-36.
12 Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients. Br J Cancer. 2010 Aug 10;103(4):560-6.
13 Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2011 May;337(2):423-32.
14 FDA Drug Development and Drug Interactions
15 Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes. Cancer Lett. 2008 Feb 18;260(1-2):163-9.
16 RNA-sequencing dissects the transcriptome of polyploid cancer cells that are resistant to combined treatments of cisplatin with paclitaxel and docetaxel. Mol Biosyst. 2017 Sep 26;13(10):2125-2134.
17 Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7). Cancer Res. 2012 Dec 15;72(24):6457-67.
18 Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. J Clin Oncol. 2005 Feb 20;23(6):1061-9.
19 Drug Interactions Flockhart Table
20 Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genes. Int J Cancer. 2004 Sep 10;111(4):617-26. doi: 10.1002/ijc.20289.
21 Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci. 2008 May;99(5):967-72.
22 Enhanced in vitro invasiveness and drug resistance with altered gene expression patterns in a human lung carcinoma cell line after pulse selection with anticancer drugs. Int J Cancer. 2004 Sep 10;111(4):484-93. doi: 10.1002/ijc.20230.
23 Enhanced chemotherapeutic efficacy of docetaxel in human lung cancer cell line via GLUT1 inhibitor. J Biochem Mol Toxicol. 2023 Jun;37(6):e23348. doi: 10.1002/jbt.23348. Epub 2023 Mar 31.
24 Comparison of burst of reactive oxygen species and activation of caspase-3 in apoptosis of K562 and HL-60 cells induced by docetaxel. Cancer Lett. 2004 Oct 8;214(1):103-13. doi: 10.1016/j.canlet.2004.03.047.
25 Down-regulation of intratumoral aromatase messenger RNA levels by docetaxel in human breast cancers. Clin Cancer Res. 2004 Dec 15;10(24):8163-9.
26 Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res. 2001 Jan 15;61(2):759-63.
27 Docetaxel-induced apoptosis of human melanoma is mediated by activation of c-Jun NH2-terminal kinase and inhibited by the mitogen-activated protein kinase extracellular signal-regulated kinase 1/2 pathway. Clin Cancer Res. 2007 Feb 15;13(4):1308-14. doi: 10.1158/1078-0432.CCR-06-2216.
28 PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line. Cancer Chemother Pharmacol. 2010 Sep;66(4):765-71. doi: 10.1007/s00280-009-1221-4. Epub 2009 Dec 30.
29 Docetaxel-induced prostate cancer cell death involves concomitant activation of caspase and lysosomal pathways and is attenuated by LEDGF/p75. Mol Cancer. 2009 Aug 28;8:68. doi: 10.1186/1476-4598-8-68.
30 Docetaxel induces p53-dependent apoptosis and synergizes with farnesyl transferase inhibitor r115777 in human epithelial cancer cells. Front Biosci. 2005 Sep 1;10:2566-75. doi: 10.2741/1720.
31 Kaempferol and quercetin stimulate granulocyte-macrophage colony-stimulating factor secretion in human prostate cancer cells. Mol Cell Endocrinol. 2008 Jun 11;287(1-2):57-64. doi: 10.1016/j.mce.2008.01.015. Epub 2008 Feb 3.
32 All-trans retinoic acid potentiates Taxotere-induced cell death mediated by Jun N-terminal kinase in breast cancer cells. Oncogene. 2004 Jan 15;23(2):426-33. doi: 10.1038/sj.onc.1207040.
33 Docetaxel Facilitates Endothelial Dysfunction through Oxidative Stress via Modulation of Protein Kinase C Beta: The Protective Effects of Sotrastaurin. Toxicol Sci. 2015 May;145(1):59-67. doi: 10.1093/toxsci/kfv017. Epub 2015 Jan 28.
34 Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles. Br J Cancer. 2006 Jun 5;94(11):1592-8. doi: 10.1038/sj.bjc.6603129.
35 The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther. 2004 Jan;3(1):59-70.
36 Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res. 2010 Oct 15;70(20):7992-8002. doi: 10.1158/0008-5472.CAN-10-0585. Epub 2010 Aug 31.
37 Anti-cancer effects of novel flavonoid vicenin-2 as a single agent and in synergistic combination with docetaxel in prostate cancer. Biochem Pharmacol. 2011 Nov 1;82(9):1100-9. doi: 10.1016/j.bcp.2011.07.078. Epub 2011 Jul 23.
38 Replication-dependent -H2AX formation is involved in docetaxel-induced apoptosis in NSCLC A549 cells. Oncol Rep. 2010 Nov;24(5):1297-305. doi: 10.3892/or_00000986.
39 Docetaxel induced cardiotoxicity. Heart. 2001 Aug;86(2):219. doi: 10.1136/heart.86.2.219.
40 Development and validation of the TGx-HDACi transcriptomic biomarker to detect histone deacetylase inhibitors in human TK6 cells. Arch Toxicol. 2021 May;95(5):1631-1645. doi: 10.1007/s00204-021-03014-2. Epub 2021 Mar 26.
41 [The mechanism of docetaxel-induced apoptosis in human lung cancer cells]. Zhonghua Zhong Liu Za Zhi. 2000 May;22(3):208-11.
42 Sensitization to docetaxel in prostate cancer cells by green tea and quercetin. J Nutr Biochem. 2015 Apr;26(4):408-15. doi: 10.1016/j.jnutbio.2014.11.017. Epub 2015 Jan 15.
43 Azidothymidine and cisplatin increase p14ARF expression in OVCAR-3 ovarian cancer cell line. Toxicol Appl Pharmacol. 2006 Oct 1;216(1):89-97. doi: 10.1016/j.taap.2006.04.015. Epub 2006 May 19.
44 Role of delta-like ligand-4 in chemoresistance against docetaxel in MCF-7 cells. Hum Exp Toxicol. 2017 Apr;36(4):328-338. doi: 10.1177/0960327116650006. Epub 2016 Jun 22.
45 Roles of CYP3A4, CYP3A5 and CYP2C8 drug-metabolizing enzymes in cellular cytostatic resistance. Chem Biol Interact. 2021 May 1;340:109448. doi: 10.1016/j.cbi.2021.109448. Epub 2021 Mar 26.
46 Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells. Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8829-36. doi: 10.1158/1078-0432.CCR-05-1728.
47 Enhanced Bax in oral SCC in relation to antitumor effects of chemotherapy. J Oral Pathol Med. 2005 Feb;34(2):93-9. doi: 10.1111/j.1600-0714.2004.00257.x.
48 Pharmacogenomics variation in drug metabolizing enzymes and transporters in relation to docetaxel toxicity in Lebanese breast cancer patients: paving the way for OMICs in low and middle income countries. OMICS. 2013 Jul;17(7):353-67. doi: 10.1089/omi.2013.0019. Epub 2013 Jun 11.
49 Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer. Breast Cancer Res Treat. 2012 Feb;131(3):849-58. doi: 10.1007/s10549-011-1500-8. Epub 2011 Apr 9.
50 PAR1-mediated NFkappaB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism. J Cell Biochem. 2005 Oct 15;96(3):641-52. doi: 10.1002/jcb.20533.
51 Regulators of G-Protein signaling RGS10 and RGS17 regulate chemoresistance in ovarian cancer cells. Mol Cancer. 2010 Nov 2;9:289. doi: 10.1186/1476-4598-9-289.
52 Mitotic checkpoint genes, hsMAD2 and BubR1, in oesophageal squamous cancer cells and their association with 5-fluorouracil and cisplatin-based radiochemotherapy. Clin Oncol (R Coll Radiol). 2008 Oct;20(8):639-46. doi: 10.1016/j.clon.2008.06.010. Epub 2008 Aug 8.
53 EGFR mediates docetaxel resistance in human castration-resistant prostate cancer through the Akt-dependent expression of ABCB1 (MDR1). Arch Toxicol. 2015 Apr;89(4):591-605. doi: 10.1007/s00204-014-1275-x. Epub 2014 Jun 3.
54 [Antisense RNA targeting survivin enhances the chemosensitivity of LOVO/Adr cells to taxotere]. Zhonghua Wei Chang Wai Ke Za Zhi. 2005 Sep;8(5):455-8.
55 Manganese superoxide dismutase is a promising target for enhancing chemosensitivity of basal-like breast carcinoma. Antioxid Redox Signal. 2014 May 20;20(15):2326-46. doi: 10.1089/ars.2013.5295. Epub 2013 Nov 14.
56 HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Breast Cancer Res Treat. 2004 Aug;86(3):197-206. doi: 10.1023/B:BREA.0000036783.88387.47.
57 Epigenetic inactivation of the CHFR gene in cervical cancer contributes to sensitivity to taxanes. Int J Oncol. 2007 Oct;31(4):713-20.
58 Differential effect of anti-apoptotic genes Bcl-xL and c-FLIP on sensitivity of MCF-7 breast cancer cells to paclitaxel and docetaxel. Anticancer Res. 2005 May-Jun;25(3c):2367-79.
59 CD146 expression in human breast cancer cell lines induces phenotypic and functional changes observed in Epithelial to Mesenchymal Transition. PLoS One. 2012;7(8):e43752. doi: 10.1371/journal.pone.0043752. Epub 2012 Aug 30.
60 Proteomic identification of differentially expressed proteins associated with the multiple drug resistance in methotrexate-resistant human breast cancer cells. Int J Oncol. 2014 Jul;45(1):448-58.
61 KIF14 promotes AKT phosphorylation and contributes to chemoresistance in triple-negative breast cancer. Neoplasia. 2014 Mar;16(3):247-56, 256.e2. doi: 10.1016/j.neo.2014.03.008.
62 The prognostic gene CRABP2 affects drug sensitivity by regulating docetaxel-induced apoptosis in breast invasive carcinoma: A pan-cancer analysis. Chem Biol Interact. 2023 Mar 1;373:110372. doi: 10.1016/j.cbi.2023.110372. Epub 2023 Feb 2.
63 Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel. Mol Cancer Ther. 2008 Jan;7(1):19-26. doi: 10.1158/1535-7163.MCT-07-0557. Epub 2008 Jan 9.
64 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
65 Genomic profiling uncovers a molecular pattern for toxicological characterization of mutagens and promutagens in vitro. Toxicol Sci. 2011 Jul;122(1):185-97.
66 Transcriptome-based functional classifiers for direct immunotoxicity. Arch Toxicol. 2014 Mar;88(3):673-89.
67 Comparison of Drug Metabolism and Its Related Hepatotoxic Effects in HepaRG, Cryopreserved Human Hepatocytes, and HepG2 Cell Cultures. Biol Pharm Bull. 2018 May 1;41(5):722-732. doi: 10.1248/bpb.b17-00913. Epub 2018 Feb 14.
68 Effect of nephrotoxicants and hepatotoxicants on gene expression profile in human peripheral blood mononuclear cells. Biochem Biophys Res Commun. 2010 Oct 15;401(2):245-50. doi: 10.1016/j.bbrc.2010.09.039. Epub 2010 Sep 16.
69 Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
70 O6-methylguanine-DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts. Int J Cancer. 1998 Sep 11;77(6):919-22.
71 Interaction of oxazaphosphorines with multidrug resistance-associated protein 4 (MRP4). AAPS J. 2010 Sep;12(3):300-8.
72 Effects of ketoconazole on cyclophosphamide metabolism: evaluation of CYP3A4 inhibition effect using the in vitro and in vivo models. Exp Anim. 2018 Feb 9;67(1):71-82.
73 Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999 Jun;27(6):655-66.
74 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
75 Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res. 1997 May 15;57(10):1946-54.
76 CYP2C9 polymorphisms in human tumors. Anticancer Res. 2006 Jan-Feb;26(1A):299-305.
77 The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes. Drug Metab Dispos. 2002 Jul;30(7):814-22.
78 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
79 Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics. 1997 Jun;7(3):211-21.
80 Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor. Cancer Chemother Pharmacol. 2009 Jun;64(1):35-43.
81 Sustained P450 expression and prodrug activation in bolus cyclophosphamide-treated cultured tumor cellsImpact of prodrug schedule on P450 gene-directed enzyme prodrug therapy. Cancer Gene Ther. 2003 Aug;10(8):571-82.
82 Establishment of the transformants expressing human cytochrome P450 subtypes in HepG2, and their applications on drug metabolism and toxicology. Toxicol In Vitro. 2001 Jun;15(3):245-56.
83 Qualitative defects of pseudocholinesterase activity. Anaesthesia. 1967 Jan;22(1):55-68.
84 Effect of cyclophosphamide on gene expression of cytochromes p450 and beta-actin in the HL-60 cell line. Eur J Pharmacol. 2002 Aug 9;449(3):197-205.
85 Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors. Leuk Res. 2007 Nov;31(11):1511-20.
86 Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
87 Chronic cyclophosphamide exposure alters the profile of rat sperm nuclear matrix proteins. Biol Reprod. 2007 Aug;77(2):303-11. doi: 10.1095/biolreprod.107.060244. Epub 2007 May 2.
88 Cyclophosphamide perturbs cytosine methylation in Jurkat-T cells through LSD1-mediated stabilization of DNMT1 protein. Chem Res Toxicol. 2011 Nov 21;24(11):2040-3. doi: 10.1021/tx2003849. Epub 2011 Nov 1.
89 Suppression of spermatogenesis in patients with Beh?et's disease treated with cyclophosphamide and colchicine. Fertil Steril. 1981 Jul;36(1):76-80. doi: 10.1016/s0015-0282(16)45622-0.
90 Development of an integrated assay in human TK6 cells to permit comprehensive genotoxicity analysis in vitro. Mutat Res Genet Toxicol Environ Mutagen. 2020 Jan;849:503129. doi: 10.1016/j.mrgentox.2019.503129. Epub 2019 Dec 27.
91 p53 mutations in cyclophosphamide-associated bladder cancer. Cancer Epidemiol Biomarkers Prev. 1998 May;7(5):397-403.
92 Cardiac toxicity of high-dose cyclophosphamide in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. Int J Hematol. 2007 Jun;85(5):408-14. doi: 10.1532/IJH97.E0620.
93 Protein assay for heme oxygenase-1 (HO-1) induced by chemicals in HepG2 cells. J Toxicol Sci. 2009 Dec;34(6):709-14. doi: 10.2131/jts.34.709.
94 Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia. 2008 Jan;22(1):179-85. doi: 10.1038/sj.leu.2404959. Epub 2007 Sep 27.
95 Induction of hsp 70 in HepG2 cells in response to hepatotoxicants. Toxicol Appl Pharmacol. 1996 Nov;141(1):117-23.
96 Profiling the immunotoxicity of chemicals based on in vitro evaluation by a combination of the Multi-ImmunoTox assay and the IL-8 Luc assay. Arch Toxicol. 2018 Jun;92(6):2043-2054. doi: 10.1007/s00204-018-2199-7. Epub 2018 Mar 29.
97 The differential effects of cyclophosphamide, epirubicin and 5-fluorouracil on apoptotic marker (CPP-32), pro-apoptotic protein (p21(WAF-1)) and anti-apoptotic protein (bcl-2) in breast cancer cells. Breast Cancer Res Treat. 2003 Aug;80(3):239-44. doi: 10.1023/A:1024995202135.
98 Distinct Orchestration and Dynamic Processes on -H2AX and p-H3 for Two Major Types of Genotoxic Chemicals Revealed by Mass Spectrometry Analysis. Chem Res Toxicol. 2020 Aug 17;33(8):2108-2119. doi: 10.1021/acs.chemrestox.0c00104. Epub 2020 Jun 17.
99 Human embryonic stem cell derived hepatocyte-like cells as a tool for in vitro hazard assessment of chemical carcinogenicity. Toxicol Sci. 2011 Dec;124(2):278-90. doi: 10.1093/toxsci/kfr225. Epub 2011 Aug 27.
100 Validation of a genotoxicity test based on p53R2 gene expression in human lymphoblastoid cells. Mutat Res. 2011 Sep 18;724(1-2):76-85. doi: 10.1016/j.mrgentox.2011.06.003. Epub 2011 Jun 17.
101 Reduction of plasma fibrinolytic activity following high-dose cyclophosphamide is neutralized in vivo by GM-CSF administration. Haematologica. 1993 Mar-Apr;78(2):105-10.
102 Inhibition of glutathione synthesis reverses Krppel-like factor 4-mediated cisplatin resistance. Cancer Chemother Pharmacol. 2012 Feb;69(2):377-85. doi: 10.1007/s00280-011-1708-7. Epub 2011 Jul 22.
103 Important role of caspase-8 for chemosensitivity of ALL cells. Clin Cancer Res. 2011 Dec 15;17(24):7605-13. doi: 10.1158/1078-0432.CCR-11-0513. Epub 2011 Oct 18.
104 Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin. Pharmacogenet Genomics. 2008 Nov;18(11):1009-15. doi: 10.1097/FPC.0b013e328313aaa4.
105 The evaluation of Cannabidiol's effect on the immunotherapy of Burkitt lymphoma. Biochem Biophys Res Commun. 2019 Nov 26;520(1):225-230. doi: 10.1016/j.bbrc.2019.10.001. Epub 2019 Oct 3.
106 [Establishment of MRP-overexpression subline of bladder carcinoma and its MDR phenotype]. Zhonghua Zhong Liu Za Zhi. 2000 Jul;22(4):273-5.
107 Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer. Breast Cancer Res Treat. 2010 Nov;124(2):433-9. doi: 10.1007/s10549-010-0840-0. Epub 2010 Mar 23.
108 T-889C IL-1alpha promoter polymorphism influences the response to oral cyclophosphamide in scleroderma patients with alveolitis. Clin Rheumatol. 2007 Jan;26(1):88-91. doi: 10.1007/s10067-006-0308-0. Epub 2006 Apr 25.
109 Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. J Clin Oncol. 2005 Sep 1;23(25):6117-25. doi: 10.1200/JCO.2005.06.075. Epub 2005 Aug 8.
110 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.